IP Library Granted Patent US 9,598,673
Granted Patent B2
US 9,598,673 · App. 12/301,597 · Granted Mar 21, 2017

Treatment of disc degenerative disease

Inventor: Thomas E. Ichim (San Diego, CA)
Assignee: Creative Medical Health
C12N5/0634A61K35/17A61K35/28A61K35/51A61K35/545A61K38/18A61K38/193C12N5/0663C12N5/0665C12N2500/36C12N2501/22C12N2501/23
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,598,673
App. No.
12/301,597
Granted
Mar 21, 2017
Kind
B2
Abstract

Methods and compositions for treating or ameliorating lower back pain by administering an effective amount of one or more cell types, alone, and/or in combination with a matrix, and/or in combination with growth factors, in order to stimulate lumbar angiogenesis, decrease inflammation, and stimulating regeneration.

Claims (6)

1. A method of inhibition of disc degeneration in a patient, said method comprising:

(a) identifying a patient having disc degenerative disease and in need of increased perfusion to the lumbar area; and

(b) injecting about 5×10 6 to about 40×10 9 mesenchymal stem cells (MSC) directly into a lumbar associated muscle proximal to a lumbar disc of said patient, wherein the cells are autologous or allogeneic non-transfected MSC expressing cellular marker CD73 and CD105; wherein the lumbar associated muscle is selected from the group consisting of psoas major muscle, multifidus muscle, transversospinalis muscle and sacrospinalis muscle, and wherein the mesenchymal stem cells augment the rate of perfusion to the area of disc degeneration without causing calcification at the administration site.

2. The method of claim 1 , wherein said cells are further identified by detecting the expression of one or more antigens selected from the group consisting of: STRO-1, CD105, CD54, CD106, HLA-I markers, vimentin, alpha-smooth muscle actin (ASMA), collagen-1 and fibronectin.

3. The method of claim 1 , wherein said cells are injected directly into the psoas major muscle.

4. The method of claim 1 , wherein said cells are injected under ultrasound guidance.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2021
From: CREATIVE MEDICAL HEALTH, INC
To: STEMSPINE INC.
Reel/Frame 055843/0004 →
SECURITY INTEREST TERMINATION Recorded Oct 10, 2014
From: KNOBBE, MARTENS, OLSON & BEAR, LLP
To: CREATIVE MEDICAL HEALTH, INC.
Reel/Frame 033959/0836 →
SECURITY INTEREST Recorded Nov 30, 2012
From: CREATIVE MEDICAL HEALTH, LLC
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 029430/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2011
From: MEDISTEM INC.
To: CREATIVE MEDICAL HEALTH, INC.
Reel/Frame 027002/0458 →
CHANGE OF NAME Recorded Sep 8, 2011
From: MEDISTEM LABORATORIES, INC.
To: MEDISTEM INC.
Reel/Frame 026872/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2009
From: ICHIM, THOMAS E.
To: MEDISTEM LABORATORIES, INC.
Reel/Frame 023310/0523 →
Continuity (2)
Provisional Application 60801957 · May 19, 2006
Related Publication 20100008992A1 · Jan 14, 2010